Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study-Reference-Cited by-同舟云学术

Tamsulosin Oral Controlled Absorption System (OCAS) in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): Efficacy and Tolerability in a Placebo and Active Comparator Controlled Phase 3a Study

Published:2005-02 Issue:2 Volume:4 Page:33-44
ISSN:1569-9056
Container-title:European Urology Supplements
language:en
Short-container-title:European Urology Supplements

Author:

Chapple Christopher R.,Al-Shukri Salman H.,Gattegno Bernard,Holmes Simon,Martínez-Sagarra José M.,Scarpa Roberto M.,van Vierssen Trip Oncko B.,Vik Viktor,van der Putten-Slob Ingrid

Publisher

Elsevier BV

Subject

Urology

Reference26 articles.

1. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men;Garraway;Br J Gen Pract,1993

2. The prevalence of prostatism: a population-based survey of urinary symptoms;Chute;J Urol,1993

3. BPH Disease Management Introduction and concluding remarks;Chapple;Eur Urol,1999

4. Integrating patient risk profiles in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in clinical practice;Speakman;Eur Urol Suppl.,2004

5. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction;Djavan;Eur Urol,1999

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Tamsulosin 0.4 mg versus 0.8 mg in management of lower urinary tract symptoms due to benign prostatic enlargement;International Urology and Nephrology;2024-01-14

2. Potential side effects of currently available pharmacotherapies in male lower urinary tract symptoms suggestive of benign prostatic hyperplasia;Expert Opinion on Drug Safety;2023-12-02

3. Do adrenergic alpha‐antagonists increase the risk of poor cardiovascular outcomes? A systematic review and meta‐analysis;ESC Heart Failure;2022-07-27

4. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis;Archivio Italiano di Urologia e Andrologia;2022-06-30

5. Evaluation of Alpha 1 Adrenoceptor Antagonist Dose Increase Therapy: An Essential Strategy for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia;Current Urology;2020-10